Autoimmune Hemolytic Anemia Treatment Market Report 2026

Autoimmune Hemolytic Anemia Treatment Market Overview

• Autoimmune Hemolytic Anemia Treatment market size has reached to $1.4 billion in 2025 • Expected to grow to $2.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Prevalence Of Autoimmune Diseases Fueling The Growth Of The Market Due To Increased Incidence And Genetic Susceptibility • Market Trend: Growing Focus on Targeted Therapies Accelerates Progress in Autoimmune Hemolytic Anemia Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Autoimmune Hemolytic Anemia Treatment Market?

Autoimmune Hemolytic Anemia (AIHA) treatment involves the use of medications and therapies to stop the immune system from attacking the body’s own red blood cells. The main purpose of treatment is to reduce red blood cell destruction, manage anemia symptoms, and prevent complications. The main types of autoimmune hemolytic anemia treatment are warm autoimmune hemolytic anemia, cold autoimmune hemolytic anemia, and other types. Warm autoimmune hemolytic anemia is a condition in which the immune system mistakenly destroys red blood cells at normal body temperature, leading to anemia. The treatments involve various drug classes, including corticosteroids, immunosuppressive agents, and other medications. These drugs are administered through different routes, such as injectable, oral, and other methods. The treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Autoimmune Hemolytic Anemia Treatment Market Growth Forecast?

The autoimmune hemolytic anemia treatment market size is expected to see strong growth in the next few years. It will grow to $2.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to targeted immunotherapy development, personalized treatment protocols, early diagnostic tools, long-term disease management, biologic therapy research. Major trends in the forecast period include increased use of corticosteroid therapy, rising adoption of immunosuppressive agents, expansion of second-line treatment options, growth in early diagnosis and monitoring, focus on reducing treatment-related complications.

Global Autoimmune Hemolytic Anemia Treatment Market Segmentation

1) By Type: Warm Autoimmune Hemolytic Anemia, Cold Autoimmune Hemolytic Anemia, Other Types 2) By Drug Class: Corticosteroids, Immunosuppressive Agents, Other Drug Classes 3) By Route Of Administration: Injectable, Oral, Other Route Of Administrations 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Warm Autoimmune Hemolytic Anemia: Primary Warm Autoimmune Hemolytic Anemia, Secondary Warm Autoimmune Hemolytic Anemia 2) By Cold Autoimmune Hemolytic Anemia: Primary Cold Agglutinin Disease (CAD), Secondary Cold Autoimmune Hemolytic Anemia 3) By Other Types: Mixed-Type Autoimmune Hemolytic Anemia, Paroxysmal Cold Hemoglobinuria (PCH), Drug-Induced Autoimmune Hemolytic Anemia

What Is The Driver Of The Autoimmune Hemolytic Anemia Treatment Market?

Rising prevalence of autoimmune diseases is expected to propel the growth of the autoimmune hemolytic anemia treatment market going forward. Autoimmune disorders refer to diseases in which the immune system mistakenly attacks the body's own tissues, causing inflammation and damage. The increasing prevalence of autoimmune diseases is largely driven by genetic predisposition, which makes individuals more susceptible to developing these conditions. The treatment of autoimmune hemolytic anemia plays a crucial role in managing the complications of autoimmune diseases by targeting and reducing the destruction of red blood cells caused by the immune system. For instance, May 2023, according to the National Institute for Health and Care Research (NIHR), is a UK-based organization that funds, supports, and delivers health and care research to improve people's health and well-being. A study of 22 million people reveals that autoimmune disorders now impact approximately one in ten individuals, with 19 autoimmune diseases affecting around 10% of the population 13% of women and 7% of men. Therefore, Rising Prevalence Of Autoimmune Diseases will drive the growth of the autoimmune hemolytic anemia treatment industry.

Key Players In The Global Autoimmune Hemolytic Anemia Treatment Market

Major companies operating in the autoimmune hemolytic anemia treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., Hutchison China MediTech Limited, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Kezar Life Sciences Inc.

Global Autoimmune Hemolytic Anemia Treatment Market Trends and Insights

Major companies operating in the autoimmune hemolytic anemia (AIHA) treatment market are focusing on advancing targeted immunotherapies to improve disease control, reduce hemolysis, and offer safer long-term management options for patients. Targeted immunotherapies aim to modulate specific immune pathways responsible for the destruction of red blood cells, thereby addressing the underlying autoimmune mechanism rather than just managing symptoms. For instance, in June 2025, HUTCHMED, a China-based biopharmaceutical company, initiated its Phase II/III registration trial (ESLIM-02) to evaluate sovleplenib, a selective Syk inhibitor, for the treatment of warm autoimmune hemolytic anemia (wAIHA). This trial is designed to assess the drug’s ability to inhibit immune-mediated hemolysis, improve hemoglobin levels, and provide a novel therapeutic option for patients with limited treatment alternatives.

What Are Latest Mergers And Acquisitions In The Autoimmune Hemolytic Anemia Treatment Market?

In October 2024, Recordati, an Italy-based pharmaceutical company, acquired global rights to Enjaymo from Sanofi for $825 million. With this acquisition, Recordati aims to expand its portfolio in rare diseases by gaining global rights to a drug for treating cold agglutinin disease (CAD), a rare type of autoimmune hemolytic anemia, enhancing its position in the specialty pharmaceuticals market. Sanofi S.A. is a France-based biopharmaceutical company specializing in the development of innovative treatments across various therapeutic areas.

Regional Insights

North America was the largest region in the autoimmune hemolytic anemia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Autoimmune Hemolytic Anemia Treatment Market?

The autoimmune hemolytic anemia treatment market consists of sales of monoclonal antibodies, complement inhibitors, blood transfusions, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Autoimmune Hemolytic Anemia Treatment Market Report 2026?

The autoimmune hemolytic anemia treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune hemolytic anemia treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.